Overview

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a certain type of skin cancer (BRAFV600E melanoma) and brain metastases (tumors that have spread to the brain).
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
GlaxoSmithKline
Treatments:
Dabrafenib
Trametinib